Integral Health Asset Management LLC Buys 300,000 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Integral Health Asset Management LLC boosted its stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 85.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 650,000 shares of the company's stock after buying an additional 300,000 shares during the period. Jasper Therapeutics accounts for approximately 1.2% of Integral Health Asset Management LLC's portfolio, making the stock its 29th largest position. Integral Health Asset Management LLC owned 4.33% of Jasper Therapeutics worth $13,897,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Jane Street Group LLC purchased a new position in shares of Jasper Therapeutics in the 3rd quarter valued at approximately $251,000. Barclays PLC lifted its position in Jasper Therapeutics by 320.7% during the third quarter. Barclays PLC now owns 16,146 shares of the company's stock valued at $304,000 after buying an additional 12,308 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Jasper Therapeutics by 13.9% during the 4th quarter. Wellington Management Group LLP now owns 27,069 shares of the company's stock valued at $579,000 after buying an additional 3,310 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Jasper Therapeutics by 239.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,391 shares of the company's stock valued at $308,000 after buying an additional 11,567 shares in the last quarter. Finally, Wells Fargo & Company MN grew its position in shares of Jasper Therapeutics by 106.7% in the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company's stock worth $159,000 after buying an additional 3,828 shares during the period. 79.85% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

JSPR has been the subject of a number of analyst reports. UBS Group decreased their target price on shares of Jasper Therapeutics from $38.00 to $33.00 and set a "buy" rating for the company in a research note on Tuesday. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of Jasper Therapeutics in a research report on Tuesday, March 11th. Finally, Oppenheimer dropped their target price on Jasper Therapeutics from $80.00 to $65.00 and set an "outperform" rating on the stock in a report on Thursday. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $62.22.

Jasper Therapeutics Trading Up 0.4%

JSPR traded up $0.02 during trading on Thursday, hitting $4.87. 89,510 shares of the company's stock traded hands, compared to its average volume of 290,523. The stock has a market capitalization of $73.16 million, a price-to-earnings ratio of -1.03 and a beta of 2.74. The company's 50 day simple moving average is $4.62 and its two-hundred day simple moving average is $11.24. Jasper Therapeutics, Inc. has a 12-month low of $3.13 and a 12-month high of $26.84.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.24). On average, equities analysts expect that Jasper Therapeutics, Inc. will post -4.47 EPS for the current year.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.